Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OSE-279 |
Synonyms | |
Therapy Description |
Limited information is currently available on OSE-279, a putative monoclonal antibody targeting PDCD1 (PD-1) (Apr 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OSE-279 | OSE279|OSE 279 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Limited information is currently available on OSE-279, a putative monoclonal antibody targeting PDCD1 (PD-1) (Apr 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05751798 | Phase Ib/II | OSE-279 | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas | Recruiting | FRA | BEL | 0 |